Which of our patients meet a criterion in their record without the step that follows?

Your practice · 143 charts connected · nothing leaves the practice

Answered on 16 September 2026

Four rules, run against the 143 charts this practice has connected. Thirty-one patients to review, each because the record already meets a criterion the guideline names, and the step that follows from it is not documented.

Nine patients: two eGFR values between 30 and 59, more than ninety days apart, with no chronic kidney disease in the chart. The criterion for stage 3 is two qualifying values, not one.
Six patients: three or more antihypertensives together with repeated hypokalaemia, and no aldosterone-to-renin ratio. Eur Heart J
Four patients: LDL above 190 mg/dl on two reports, with no assessment for familial hypercholesterolaemia. Eur Heart J
Twelve patients: age, AST, ALT and platelets all present and the FIB-4 never calculated. The score needs no new test. J Hepatol

Every line names the criterion the record meets, not a diagnosis, and no model is guessing: the rules are the ones the guidelines state. The charts were read where they are, and nothing left the practice.

Across the practiceBuilt from the chart, in the record

Criteria met, step not taken

143 charts read against four documented rules
Thirty-one patients to review, with what is still to confirm
No diagnosis and no prediction, and nothing left the practice

Every line carries the document it was read from

1.2024 ESC Guidelines for the management of elevated blood pressure and hypertension.European Heart Journal. 2024;45:3912-4018. McEvoy JW, McCarthy CP, Bruno RM, et al.Guideline
SummaryIntroduces the category “elevated blood pressure” (120 to 139/70 to 89 mmHg) and recommends a treated systolic target of 120 to 129 mmHg for most adults if tolerated. Home blood pressure monitoring is recommended to confirm the diagnosis and guide treatment: seated after five minutes of rest, two readings morning and evening for at least three, ideally seven days. Combination therapy is preferred when one drug is insufficient.
Source
Issuing body: European Society of Cardiology
Published: August 2024
Grading system: ESC classes of recommendation I–III, levels of evidence A–C
Scope
Target population: Adults with elevated blood pressure or hypertension
Scope: Diagnosis, targets, lifestyle, drug therapy, monitoring
2.2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.European Heart Journal. 2020;41:111-188. Mach F, Baigent C, Catapano AL, et al.Guideline
SummaryLDL cholesterol goals by risk category: below 116 mg/dl at low risk, below 100 mg/dl at moderate risk, below 70 mg/dl at high risk, below 55 mg/dl at very high risk. Statins first, ezetimibe second, PCSK9 inhibitors third. Statin interactions run mainly through CYP3A4 (atorvastatin, simvastatin) and OATP1B1; monitoring of ALT and CK is defined.
Source
Issuing body: ESC and European Atherosclerosis Society
Published: January 2020; focused update 2025
Grading system: ESC classes of recommendation I–III, levels of evidence A–C
Scope
Target population: Adults with dyslipidaemia or elevated cardiovascular risk
Scope: Targets, drugs, monitoring, special situations
3.EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).Journal of Hepatology. 2024;81:492-542. European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity.Guideline
SummarySteatotic liver disease with at least one cardiometabolic risk factor is MASLD. In primary care, patients with steatosis or metabolic risk should have non-invasive fibrosis assessment with FIB-4: below 1.3 rules out advanced fibrosis with repeat testing in one to three years; 1.3 or above calls for elastography or referral. Treatment is weight reduction, physical activity and control of the metabolic risk factors.
Source
Issuing body: EASL, EASD, EASO
Published: September 2024
Grading system: GRADE
Scope
Target population: Adults with steatotic liver disease and metabolic risk factors
Scope: Case finding, fibrosis assessment, management

What would you like to ask next?

1Which findings were never followed up?2Which preventive care is due for her?3Which findings are still open?

This is a sample workspace. Click one of the questions. To ask your own questions, request access.

No patientMosaic